Boston-based biomarker assay developer Ultivue and artificial intelligence (AI) software developer Paige have established a collaborative agreement to develop and market AI-powered spatial immunophenotype capabilities for pharmaceutical and research customers.
Efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue's novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels, the companies said.
